174 related articles for article (PubMed ID: 15007638)
1. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
Mougenot P; Pinguet F; Fabbro M; Culine S; Poujol S; Astre C; Bressolle F
Cancer Chemother Pharmacol; 2004 Jun; 53(6):503-12. PubMed ID: 15007638
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of oral busulfan in children.
Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of melphalan as a single-agent infused over a 24-hour period with individual adapted dosing in patients with recurrent epithelial ovarian cancer.
Mougenot P; Fabbro M; Bressolle F; Pouessel D; Culine S; Pinguet F
Oncol Rep; 2006 Jan; 15(1):237-41. PubMed ID: 16328062
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation.
Pinguet F; Martel P; Fabbro M; Petit I; Canal P; Culine S; Astre C; Bressolle F
Anticancer Res; 1997; 17(1B):605-11. PubMed ID: 9066587
[TBL] [Abstract][Full Text] [Related]
7. Modeling plasma and saliva topotecan concentration time course using a population approach.
Boucaud M; Pinguet F; Culine S; Poujol S; Astre C; Gomeni R; Bressolle F
Oncol Res; 2003; 13(4):211-9. PubMed ID: 12659422
[TBL] [Abstract][Full Text] [Related]
8. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
Variol P; Nguyen L; Tranchand B; Puozzo C
Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
[TBL] [Abstract][Full Text] [Related]
9. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer.
Gauvin A; Pinguet F; Culine S; Astre C; Gomeni R; Bressolle F
Clin Cancer Res; 2000 Jul; 6(7):2690-5. PubMed ID: 10914711
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy.
Faltaos DW; Hulot JS; Urien S; Morel V; Kaloshi G; Fernandez C; Xuan kH; Leblond V; Lechat P
Cancer Chemother Pharmacol; 2006 Nov; 58(5):626-33. PubMed ID: 16528531
[TBL] [Abstract][Full Text] [Related]
11. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of high-dose melphalan in adults: influence of renal function.
Kergueris MF; Milpied N; Moreau P; Harousseau JL; Larousse C
Anticancer Res; 1994; 14(6A):2379-82. PubMed ID: 7825976
[TBL] [Abstract][Full Text] [Related]
13. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
15. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
16. Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion.
Choi KE; Ratain MJ; Williams SF; Golick JA; Beschorner JC; Fullem LJ; Bitran JD
Cancer Res; 1989 Mar; 49(5):1318-21. PubMed ID: 2645050
[TBL] [Abstract][Full Text] [Related]
17. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.
Tricot G; Alberts DS; Johnson C; Roe DJ; Dorr RT; Bracy D; Vesole DH; Jagannath S; Meyers R; Barlogie B
Clin Cancer Res; 1996 Jun; 2(6):947-52. PubMed ID: 9816255
[TBL] [Abstract][Full Text] [Related]
18. In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer.
Mougenot P; Bressolle F; Culine S; Solassol I; Poujol S; Pinguet F
Anticancer Res; 2006; 26(3B):2197-203. PubMed ID: 16821586
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
Latz JE; Chaudhary A; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]